Paper Details

  1. Home
  2. Paper Details

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Author: , AdvaniRanjana, BartlettNancy L, BeladaDavid, ChristensenJacob Haaber, Domingo-DomenechEva, FanaleMichelle, FeldmanTatyana, HorwitzSteven, HuaZhaowei, HüttmannAndreas, IllidgeTim, IllésÁrpád, IyerSwaminathan, KimWon Seog, LennardAnne, LittleMeredith, ManleyThomas, MorschhauserFranck, O'ConnorOwen A, ProBarbara, RaoShangbang, RossiGiuseppe, SavageKerry J, ShustovAndrei, TobinaiKensei, TrümperLorenz, TsukasakiKunihiro, WooleryJoseph, YehSu-Peng, YuenSam, ZinzaniPier Luigi

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.
Paper Details　
Original Abstract of the Article :
Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and predn...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/30522922

データ提供：米国国立医学図書館（NLM）

A New Hope for CD30-Positive Peripheral T-Cell Lymphoma

In the realm of oncology, we're always searching for new weapons to combat those pesky tumors. This research delves into the world of CD30-positive peripheral T-cell lymphomas, a type of cancer that's notoriously tricky to treat. The authors conducted a phase 3 clinical trial to compare the effectiveness and safety of two chemotherapy regimens for this specific type of lymphoma. The study, called ECHELON-2, pitted brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (A+CHP) against the traditional CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). The study yielded promising results, suggesting that brentuximab vedotin, a targeted therapy, might provide a more effective and tolerable option for patients with CD30-positive peripheral T-cell lymphoma.

The ECHELON-2 Trial: A Beacon of Hope

The results of the ECHELON-2 trial are encouraging. Brentuximab vedotin, in combination with A+CHP, demonstrated a favorable safety profile and showed potential for improved efficacy compared to the standard CHOP regimen. This suggests that this novel treatment approach could be a game-changer for patients with CD30-positive peripheral T-cell lymphoma.

Navigating the Desert of Lymphoma Treatment

Lymphoma treatment can be a long and challenging journey. This research provides a glimmer of hope for patients with CD30-positive peripheral T-cell lymphoma, suggesting that brentuximab vedotin combined with A+CHP may offer a better chance at survival with fewer side effects. It's crucial to consult with your doctor to determine the best treatment plan for your individual needs.

Dr.Camel's Conclusion

This study offers a promising path forward for patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin, a targeted therapy, combined with the A+CHP regimen, seems to be a viable option. It's exciting to see researchers making strides in the fight against these challenging cancers.

Date :
  1. Date Completed 2019-02-07
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

30522922

DOI: Digital Object Identifier

NIHMS1515984

Related Literature

Article Analysis
・Effects of brentuximab vedotin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.